Patriot Financial Group Insurance Agency LLC Purchases 24,316 Shares of CRISPR Therapeutics AG $CRSP

Patriot Financial Group Insurance Agency LLC lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 104.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 47,550 shares of the company’s stock after purchasing an additional 24,316 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in CRISPR Therapeutics were worth $2,262,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. UBS Group AG increased its position in shares of CRISPR Therapeutics by 7.7% during the 4th quarter. UBS Group AG now owns 2,524,144 shares of the company’s stock valued at $132,366,000 after purchasing an additional 180,580 shares during the last quarter. SR One Capital Management LP lifted its position in CRISPR Therapeutics by 94.4% in the third quarter. SR One Capital Management LP now owns 2,038,763 shares of the company’s stock worth $132,132,000 after buying an additional 989,812 shares during the last quarter. Clough Capital Partners L P bought a new stake in CRISPR Therapeutics in the third quarter worth $1,491,000. Norges Bank purchased a new position in CRISPR Therapeutics during the fourth quarter worth $25,706,000. Finally, Leonteq Securities AG purchased a new position in CRISPR Therapeutics during the fourth quarter worth $1,155,000. Institutional investors own 69.20% of the company’s stock.

Wall Street Analyst Weigh In

CRSP has been the topic of a number of analyst reports. Morgan Stanley set a $60.00 price objective on shares of CRISPR Therapeutics and gave the company an “equal weight” rating in a research report on Thursday, June 11th. Piper Sandler restated an “overweight” rating and issued a $110.00 target price (up from $105.00) on shares of CRISPR Therapeutics in a report on Tuesday, March 17th. UBS Group set a $80.00 target price on CRISPR Therapeutics in a research report on Friday, June 12th. Evercore restated an “outperform” rating and issued a $76.00 price target on shares of CRISPR Therapeutics in a report on Monday, May 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $67.78.

CRISPR Therapeutics Price Performance

CRSP opened at $54.92 on Monday. The business’s 50-day moving average is $52.72 and its two-hundred day moving average is $53.04. CRISPR Therapeutics AG has a 1 year low of $44.12 and a 1 year high of $78.48. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 17.96. The firm has a market capitalization of $5.30 billion, a PE ratio of -8.83 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The firm had revenue of $1.46 million for the quarter. Research analysts anticipate that CRISPR Therapeutics AG will post -4.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the sale, the insider owned 19,357 shares of the company’s stock, valued at approximately $1,076,636.34. This trade represents a 16.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.